


CLAIMS

1. A compound of formula (I)



5

or a salt thereof

wherein:

R^1 is $-C_{1-3}$ alkyl or cyclopropyl;

R^2 is $-C_{0-3}$ alkyl-cycloalkyl, wherein the cycloalkyl group is optionally substituted with one, two
10 or three R^5 groups which may be the same or different; or

R^2 is $-C_{0-4}$ alkyl-heterocyclyl or $-(CH_2)_pO$ -heterocyclyl wherein each heterocyclyl is optionally substituted by one or two R^9 groups which may be the same or different; or

R^2 is H, $-CH_3$, $-C_{2-6}$ alkyl optionally substituted by one, two, three, four or five fluoro, $-C_{2-6}$ alkylOR⁶, $-C_{2-6}$ alkylNR^{10a}R^{11a}, $-(CH_2)_mSO_2C_{1-3}$ alkyl, $-(CH_2)_mSO_2NR^{10}R^{11}$, $-(CH_2)_mC(O)NR^{10}R^{11}$, $-(CH_2)_mCN$, $-(CH_2)_mCO_2R^6$, $-(CH_2)_mNHCO_2C_{1-4}$ alkyl, $-(CH_2)_mNHC(O)C_{1-4}$ alkyl or $-(CH_2)_n$ heteroaryl
15 wherein the heteroaryl is optionally substituted by one or two R^7 groups which may be the same or different;

R^3 is H, $-C_{1-4}$ alkyl, cyclopropyl, $-CH_2F$, $-C_{1-3}$ alkylOR⁶ or $-C_{1-3}$ alkylCN;

R^4 is phenyl or a heteroaryl group wherein each are optionally substituted by one, two or three
20 R^7 groups which may be the same or different;

each R^5 is independently halo, $-C_{0-6}$ alkyl-R⁸, $-O-C_{2-6}$ alkyl-R⁸, $-OCH_2$ phenyl, $-CN$ or $-SO_2C_{1-3}$ alkyl;

R^6 is H or $-C_{1-4}$ alkyl;


each R^7 is independently oxo, halo, $-C_{1-4}$ alkyl optionally substituted by one, two or three fluoro,
25 $-C_{0-3}$ alkylOR⁶, $-OC_{2-3}$ alkylOR⁶, $-C_{0-3}$ alkylNR^{10}R^{11}, $-C_{0-3}$ alkyl-CONR^{10}R^{11}, $-CN$, $-SO_2-C_{1-3}$ alkyl, $-SO_2NR^{10}R^{11}$ or $-SO_2$ phenyl optionally substituted by $-C_{1-4}$ alkyl ;}}

R^8 is H, $-OR^6$, $-NR^{10}R^{11}$ or heteroaryl;

each R^9 is independently halo, $-C_{1-4}$ alkyl, cyclopropyl, cyclobutyl, $-CH_2CF_3$, $-CH_2CHF_2$, $-CH_2CH_2F$, $-OCH_2CH_2OR^6$, $-C_{0-3}$ alkylOR⁶, $-C_{0-3}$ alkylNR<sup>10}R^{11}, $-NHCH_2CH_2OR^6$, $-NHCO_2C_{1-4}$ alkyl, oxo, $-C(O)R^6$, $-C(O)OR^6$ or $-C(O)NR^{10}R^{11}$;
30</sup>

- R¹⁰ and R¹¹ are each independently selected from H and -C₁₋₃alkyl; or R¹⁰ and R¹¹ may join together with the nitrogen to which they are attached, to form a 4 to 7-membered heterocyclyl optionally substituted by one or two substituents independently selected from -C₁₋₃alkyl optionally substituted with one, two or three fluorine atoms, -C₂₋₄alkylOH, -OH and F;
- 5 R^{10a} and R^{11a} are each independently selected from H and -C₁₋₃alkyl;
 m is an integer selected from 2, 3 or 4;
 n is an integer selected from 0, 1, 2, 3 or 4; and
 p is an integer selected from 2, 3 or 4.
2. A compound or salt thereof according to claim 1 wherein R¹ is methyl.
- 10 3. A compound or salt thereof according to claim 1 or claim 2 wherein R² is a -C₀₋₃alkyl-C₃₋₇cycloalkyl group, wherein the C₃₋₇cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclohexyl or bicyclo[3.1.0]hexanyl said groups being optionally substituted with one, two or three R⁵ groups which may be the same or different.
4. A compound or a salt thereof according to claim 1 or claim 2 wherein R² is -C₀₋₄alkyl-
 15 heterocyclyl wherein the heterocyclyl is selected from oxetanyl, tetrahydrofuranyl, tetrahydro-2H-pyran, morpholinyl, piperidinyl, piperazinyl, (1*r*,5*s*)-3-oxabicyclo[3.1.0]hexanyl and (1*r*,5*s*)-3-azabicyclo[3.1.0]hexanyl said groups being optionally substituted by one or two R⁹ groups which may be the same or different.
5. A compound or salt thereof according to claim 1 or claim 2 wherein R² is methyl, ethyl, propyl,
 20 *iso*-propyl, butyl, -CH₂CH₂CH(CH₃)₂, -CH₂CH(CH₃)₂, -CH₂CH₂OR⁶, -CH₂CH₂CH₂OR⁶, -CH₂CH(CH₃)OR⁶, -CH₂CH₂CH(CH₃)OR⁶, -CH₂CH₂CH(CH₃)NR¹⁰R¹¹, -CH₂CH₂CH₂NR¹⁰R¹¹, -(CH₂)_mSO₂CH₃, -(CH₂)_mC(O)NHCH₃, -(CH₂)_mCN, -(CH₂)_mCO₂R⁶, -(CH₂)_mCF₃ and -(CH₂)_mNHCO₂C(CH₃)₃.
6. A compound or salt thereof according to claim 1 or claim 2 wherein R² is -(CH₂)_nC₅₋₆heteroaryl wherein the C₅₋₆heteroaryl group is selected from furanyl, thienyl, pyrrolyl, triazolyl, thiazolyl, oxazolyl,
 25 isoxazolyl, oxadiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrazinyl and pyrimidinyl said groups being optionally substituted by one or two substituents independently selected from halo, C₁₋₄alkyl, C₃₋₄cycloalkyl and -C₀₋₃alkylOR⁶.
7. A compound or salt thereof according to any of the preceding claims wherein R³ is H, methyl, ethyl, -CH₂F, -CH₂OH, -CH(OH)CH₃, -CH₂OMe or -CH₂CN.
- 30 8. A compound or salt thereof according to any of the preceding claims wherein R⁴ is unsubstituted phenyl or is phenyl substituted by one or two R⁷ groups which may be the same or different selected from halo, -C₁₋₄alkyl, -C₀₋₃alkylOR⁶ and -CN.
9. A compound or salt thereof according to any one of claims 1 to 7 wherein R⁴ is a heteroaryl group selected from the group consisting of pyridyl, indolyl and pyrrolopyridinyl said groups being
 35 optionally substituted by one, two or three R⁷ groups which may be the same or different.
10. A compound which is selected from Examples 1 to 261, or a salt thereof.
11. A compound which is selected from

- Λ^5 -((1*r*,4*S*)-4-hydroxycyclohexyl)- Λ^{β} -methyl-1-((*S*)-1-phenylethyl)-1*H*-pyrazole-3,5-dicarboxamide;
 Λ^5 -((1*R*,3*R*,5*S*,6*r*)-3-hydroxybicyclo[3.1.0]hexan-6-yl)- Λ^{β} -methyl-1-((*S*)-1-phenylethyl)-1*H*-pyrazole-3,5-dicarboxamide
 Λ^5 -((1*R*,5*S*,6*r*)-3-oxabicyclo[3.1.0]hexan-6-yl)-1-((*S*)-1-(4-chlorophenyl)ethyl)- Λ^{β} -methyl-1*H*-pyrazole-3,5-dicarboxamide;
 5 (*S*)- Λ^{β} -methyl-1-(1-phenylethyl)- Λ^5 -(1*H*-pyrazol-4-yl)-1*H*-pyrazole-3,5-dicarboxamide;
 1-((*S*)-1-(4-chlorophenyl)ethyl)- Λ^5 -((1*R*,3*R*,5*S*,6*r*)-3-hydroxybicyclo[3.1.0]hexan-6-yl)- Λ^{β} -methyl-1*H*-pyrazole-3,5-dicarboxamide;
 1-((*S*)-1-(3-chlorophenyl)ethyl)- Λ^5 -((1*R*,3*R*,5*S*,6*r*)-3-hydroxybicyclo[3.1.0]hexan-6-yl)- Λ^{β} -methyl-1*H*-pyrazole-3,5-dicarboxamide;
 10 Λ^5 -((1*R*,3*R*,5*S*,6*r*)-3-hydroxybicyclo[3.1.0]hexan-6-yl)- Λ^{β} -methyl-1-((*S*)-1-phenylpropyl)-1*H*-pyrazole-3,5-dicarboxamide; and
 Λ^5 -((1*r*,4*S*)-4-methoxycyclohexyl)- Λ^{β} -methyl-1-((*S*)-1-phenylethyl)-1*H*-pyrazole-3,5-dicarboxamide
 or a salt thereof.
- 15 12. A compound which is Λ^5 -((1*R*,5*S*,6*r*)-3-oxabicyclo[3.1.0]hexan-6-yl)- Λ^{β} -methyl-1-((*S*)-1-phenylethyl)-1*H*-pyrazole-3,5-dicarboxamide represented by the formula



- or a salt thereof.
13. A compound according to any of the preceding claims or a pharmaceutically acceptable salt thereof.
 20 14. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as defined in claim 13 and one or more pharmaceutically acceptable excipients.
 15. A combination comprising a compound or a pharmaceutically acceptable salt thereof as defined in claim 13 together with one or more other therapeutically active agents.
 25 16. A compound or a pharmaceutically acceptable salt thereof as defined in claim 13, for use in therapy.
 17. A compound or a pharmaceutically acceptable salt thereof as defined in claim 13, for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated.
 18. A compound for use according to claim 17, wherein the disease or condition is an acute or
 30 chronic autoimmune and/or inflammatory condition.
 19. A compound for use according to claim 17, wherein the disease or condition involves an inflammatory response to an infection with bacteria, a virus, fungi, a parasite or their toxins.
 20. A compound for use according to claim 17, wherein the disease or condition is a viral infection.
 21. A compound for use according to claim 17, wherein the disease or condition is cancer.

22. A compound for use according to claim 17, wherein the disease or condition is rheumatoid arthritis.
23. The use of a compound or a pharmaceutically acceptable salt thereof as defined in claim 13, in the manufacture of a medicament for the treatment of a disease or condition for which a bromodomain inhibitor is indicated.
24. A method of treatment of a disease or condition for which a bromodomain inhibitor is indicated in a subject in need thereof which comprises administering a therapeutically effective amount of compound or a pharmaceutically acceptable salt thereof as defined in claim 13.
25. A method of treatment according to claim 24, wherein the disease or condition is an acute or chronic autoimmune and/or inflammatory condition.
26. A method of treatment according to claim 24, wherein the disease or condition involves an inflammatory response to an infection with bacteria, a virus, fungi, a parasite or their toxins.
27. A method of treatment according to claim 24, wherein the disease or condition is a viral infection.
28. A method of treatment according to claim 24, wherein the disease or condition is cancer.
29. A method of treatment according to claim 24, wherein the disease or condition is rheumatoid arthritis.
30. A method of treatment according to any one of claims 24 to 29, wherein the subject is a human.